Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis

P. BauermannDepartment of Ophthalmology, St. Franziskus Hospital, Muenster, GermanyCorrespondence[email protected]

A. HeiligenhausDepartment of Ophthalmology, St. Franziskus Hospital, Muenster, Germany;Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany

C. HeinzDepartment of Ophthalmology, St. Franziskus Hospital, Muenster, Germany;Department of Ophthalmology, University of Duisburg-Essen, Essen, Germany

https://orcid.org/0000-0002-2814-4327

References

Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376:1637–1646. doi:10.1056/NEJMoa1614160.
PubMed Web of Science ®Google Scholar
Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77:1003–1011. doi:10.1136/annrheumdis-2017-212089.
PubMed Web of Science ®Google Scholar
Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol (Hoboken, NJ). 2017;69:668–675. doi:10.1002/art.39940.
PubMed Web of Science ®Google Scholar
Tappeiner C, Mesquida M, Adan A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43:2183–2188. Epub 2016/09/17. doi:10.3899/jrheum.160231.
PubMed Web of Science ®Google Scholar
Pichi F, Nucci P, Baynes K, Lowder CY, Srivastava SK. Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis. Int Ophthalmol. 2017;37:221–228. doi:10.1007/s10792-016-0265-9.
PubMed Web of Science ®Google Scholar
Hall S, Nash P, Rischmueller M, et al. Tofacitinib, an oral Janus Kinase inhibitor: pooled efficacy and safety analyses in an Australian rheumatoid arthritis population. Rheumatol Ther. 2018; Epub 2018/06/28. doi:10.1007/s40744-018-0118-2.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date